A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with relapsed / refractory mantle cell lymphoma (MCL).
Relapsed / Refractory Mantle Cell Lymphoma (MCL)
DRUG: TQ-B3525
Objective response rate (ORR) assessed by Independent Review Committee (IRC), Percentage of subjects achieving complete response (CR) and partial response (PR) based on investigator., up to 12 months
Disease control rate（DCR）, Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 12 months|Duration of Response (DOR), DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment., up to 12 months|Progression-free survival (PFS), PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause., up to 12 months|Overall survival (OS), OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up., up to 18 months|Biomarkers, To assess the changes of genes related to PI3K pathway and bypass in the tissues and / or plasma of enrolled patients., up to 12 months
This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with relapsed / refractory mantle cell lymphoma (MCL).